A Phase 3 interventional study of KLH-2109+ Leurprorelin acetate Placebo and KLH-2109 Placebo + Leurprorelin acetate in Menorrhagia and Uterine Fibroids, sponsored by JW Pharmaceutical. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus.
The primary objectives of this trial were to answer the following questions:
Investigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.
Participants will be required to follow:
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3
206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.
This study's planned enrollment of 254 is above the median of 95 across 149 interventional studies indexed under Menorrhagia.
Browse Menorrhagia studies →JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
KLH-2109: 200mg/day for 24 weeks(PO, QD) Leurprorelin acetate Placebo: Once every 4 weeks, subcutaneous injection
Drug: KLH-2109+ Leurprorelin acetate Placebo
KLH-2109 Placebo: 24 weeks(PO, QD) Leurprorelin acetate : 1.88mg or 3.75mg, Once every 4 weeks, subcutaneous injection
Drug: KLH-2109 Placebo + Leurprorelin acetate
KLH-2109 200mg/day for 24 weeks(PO, QD) Leurprorelin acetate Placebo: Once every 4 weeks, subcutaneous injection
Also known as: KLH-2019+ Leurprorelin acetate Placebo
KLH-2109 Placebo: for 24 weeks(PO, QD) Leurprorelin acetate Placebo: 1.88mg or 3.75mg , Once every 4 weeks, subcutaneous injection
Also known as: KLH-2019 Placebo + Leurprorelin acetate Placebo
Proportion of subjects with a total PBAC score < 10
Proportion of subjects with a total PBAC score \< 10 from Week 6 to the day before Week 12 after administration of the investigational product
Time frame: Week 6 to the day before Week 12
Proportion of subjects with a total PBAC score < 10
Proportion of subjects with a total PBAC score \< 10 from Week 2 to the day before Week 6 after administration of the investigational product
Time frame: Week 6 , Week12, Week 18, Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.
Of 17 phase 3 interventional studies under Menorrhagia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 35. This study's planned 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.